Andrew Dunn

@AndrewE_Dunn

Senior biopharma correspondent at @endpts | Previously @BusinessInsider @BioPharmaDive | [email protected] | Signal (sources only, no PR): adunn123.30

New York, NY

Joined March 2015

2KFollowing

11KFollowers

Andrew Dunn@AndrewE_Dunn · Jul 10

Thanks to @zachweinberg for joining us on Post-Hoc Live. Curious for rest of the biotech world to weigh in as well on his concerns w/ China: what's valid, what's not?

TTweets from Zach Weinberg@zachweinberg · Jul 10

I did a lot of talking about early stage biotech + China and some of the competitive issues around a level playing field (or lack thereof). Tried to make the content approachable for people who aren't in the industry. YouTube link here: youtube.com/watch?v=7kkmBX…

1.0K

Andrew Dunn@AndrewE_Dunn · Jul 10

EEndpoints News@endpts · Jul 10

Is China a threat, or an investment opportunity? Post-Hoc Live with Curie.Bio CEO Zach Weinberg x.com/i/broadcasts/1…

14.0K

Andrew Dunn@AndrewE_Dunn · Jul 9

Part 2 of my pay series, this time focusing on typical employee compensation Across 177 biopharmas that disclosed median pay, the typical worker made $224,729 in 2024 — a 13% bump from $199,048 in 2023 Highest-paying biopharmas of last year: endpoints.news/biopharma-pay-…

AndrewE_Dunn's tweet card. Median employee pay at public life sciences companies reached $224,729 in 2023, up 13% from previous year, per Endpoints News analysis of 177 biopharma companies.

6.0K

Andrew Dunn@AndrewE_Dunn · Jul 9

NEW: RevMed will pair its unique library of molecular structures and data with the AI models developed by Iambic Therapeutics, the two biotechs announced Wednesday. $RVMD to pay $25 million in short term to Iambic through upfront + near-term milestones: endpoints.news/revolution-and…

AndrewE_Dunn's tweet card. Revolution Medicines has become one of the industry's most valuable pre-commercial companies thanks to its pipeline of clinical-stage cancer drugs. CEO Mark Goldsmith is pressing ahead on ...

1.0K

Andrew Dunn@AndrewE_Dunn · Jul 8

This has turned into an annual summer tradition of mine — analyzing compensation trends across the biopharma world In today's story, I analyzed 475 CEO pay packages, finding the 20 highest-paid for 2024: endpoints.news/the-highest-pa…

AndrewE_Dunn's tweet card. Biopharma CEO median pay hit $4.73M in 2024, up 40%. 20 CEOs made over $20M, including Pfizer's Bourla, Vertex's Kewalramani, Amgen's Bradway & Royalty Pharma's Legorreta.

5.0K

Andrew Dunn@AndrewE_Dunn · Jul 7

NEW: I interviewed KalVista CEO Ben Palleiko on the heels of their FDA approval for its HAE drug. "We were fairly blindsided by when your report came out, because until then, we hadn’t had the slightest idea.” More here in my latest for @endpts: endpoints.news/kalvista-ceo-t…

AndrewE_Dunn's tweet card. The company felt 'fairly blindsided' upon reading the report that FDA Commissioner Marty Makary had briefly yet unsuccessfully tried to intervene in the review of its newly-approved HAE drug.

3.0K

Andrew Dunn@AndrewE_Dunn · Jul 7

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene endpoints.news/fda-approves-k…

1.0K

Andrew Dunn@AndrewE_Dunn · Jul 2

NEW: An inside look at the growing divide among US biotech investors over China's ascent Some VCs are capitalizing on China's rise by licensing in molecules and forming NewCo's. Others like @zachweinberg see a threat to the US biotech industry: endpoints.news/us-investors-d…

AndrewE_Dunn's tweet card. US investors debate response to China's rise in drug development, with some seeing a national security threat while others embrace collaboration. FDA and policymakers consider reforms to maintain...

3.0K

Andrew Dunn@AndrewE_Dunn · Jun 30

NEW: The OpenAI-backed biotech startup Chai Discovery announced a new suite of AI models today, called Chai-2 The main result: making de novo antibodies with a 19% hit rate on average, which @zavaindar called "fucking killer" endpoints.news/openai-backed-…

AndrewE_Dunn's tweet card. Chai Discovery reports 19% success rate with new AI models (Chai-2) for antibody design, surpassing competitors' results. Company tested against 39 drug targets including TNF-alpha and TSLP.

149

26.0K

Andrew Dunn@AndrewE_Dunn · Jun 27

NEW: Some expert reaction & further context around FDA head Marty Makary's unsuccessful attempt to intervene in KalVista's drug review: endpoints.news/fda-head-makar…

AndrewE_Dunn's tweet card. FDA Commissioner Marty Makary’s unsuccessful attempt to intervene in an ongoing drug review, as described by multiple agency sources, raises further concerns about the regulator under its new...

795

Andrew Dunn@AndrewE_Dunn · Jun 24

If you work at the FDA, I am interested to hear more about your perspective. Please consider reaching out to me on Signal: my username is adunn123.30 endpoints.news/sources-fda-ch…

AndrewE_Dunn's tweet card. FDA Commissioner Marty Makary reportedly attempted to reject KalVista Pharmaceuticals' drug application, sources said. An HHS spokesperson calls the claim 'totally false.'

11.0K

Andrew Dunn@AndrewE_Dunn · Jun 24

Exclusive: FDA's Makary sought rejection of KalVista’s drug in an unusual move by commissioner, sources say My latest — endpoints.news/sources-fda-ch…

17.0K

Andrew Dunn@AndrewE_Dunn · Jun 18

Join the @endpts team live from the BIO floor — we're talking conference takeaways, state of the biotech market, and more at 1:30p ET: youtube.com/watch?v=MGlDIc…

1.0K

Andrew Dunn@AndrewE_Dunn · Jun 17

NEW: After spending its first year in relative quiet since its billion-dollar public debut, Xaira is out with its first preprint I talked with Xaira's lead scientist on the project, which includes releasing 8 million cells' worth of Perturb-seq: endpoints.news/ai-biotech-xai…

AndrewE_Dunn's tweet card. Xaira Therapeutics releases first research paper on scaled-up Perturb-seq method and dataset, aiming to build AI models for virtual cells. Led by VP Ci Chu.

3.0K

Andrew Dunn@AndrewE_Dunn · Jun 12

an enjoyable 40 minute chat i got a sudden sense of dread an hour before the interview, thinking it would be equivalent to a job interview, and that i would be asked to explain, live, why typical self attention doesn't work for alphafold2 MSA inputs. this did not happen

oowl@owl_posting · Jun 11

during my unemployment, i have done many New Things, such as finishing half of The Sopranos and doing 2 V3’s in 24 hours, i will do another New Thing and chat live w/ the esteemed @AndrewE_Dunn and @ArmstrongDrew yt link: youtube.com/live/S2AQ1mFhT…

7.0K

Andrew Dunn@AndrewE_Dunn · Jun 12

Coming up at the top of the hour — tune in!

DDrew Armstrong@ArmstrongDrew · Jun 12

We're bringing on a guest who I've wanted to have on for a long time — the one and only @owl_posting, joining me and @AndrewE_Dunn. See you here at noon! youtube.com/live/S2AQ1mFhT…

1.0K